News | July 20, 2021
Balaxi Pharmaceuticals Q1 revenue increases by 12%
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
The first batch will be shipped to the Gamaleya Center for the quality control
Oxygen Park is a concept where a two-layer layout is being used to plant oxygen releasing trees which releases oxygen for 24 hours
TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Subscribe To Our Newsletter & Stay Updated
